The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2021 | Mechanism of action of GTB-3550 TriKE
Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, discusses the mechanism of action and rationale behind the development of GTB-3550, a tri-specific killer engager (TriKE®) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
